Using the “Precaution” label leaves this window open: that the subsequent shot could also be a brand new vaccine relatively than simply the third shot.
As of Saturday, 12.04 crore individuals above 60 years of age have obtained their first dose of vaccine; And 9.21 crores have been absolutely vaccinated. Official figures additionally present that 1.03 crore healthcare employees have obtained their first dose, and 96 lakh have been absolutely vaccinated; 1.83 crore frontline employees have obtained their first dose, and 1.68 crore have been absolutely vaccinated. Which successfully implies that over 11 crore beneficiaries will likely be eligible for the “precautionary dose”.
“There is some clarity that if an additional dose is given to a beneficiary, there may not be a single vaccine, at least in the case of inactivated whole virus or adenovirus vector COVID-19 vaccine. So the initial consensus is that a beneficiary cannot take Covishield or three doses of Covaxin,” the sources mentioned.
Sources mentioned that there’s a excessive chance that the precautionary dose will likely be a vaccine from a unique platform. Several choices are more likely to be accessible within the coming months. is the primary Hyderabad primarily based Biologicals E’s Corbevax, A protein sub-unit of the COVID-19 vaccine.
It differs from inactivated whole-cell vaccines by involving solely the antigenic components of the virus, to set off a protecting immune response. Bio E’s vaccine candidate consists of an antigen developed by the Texas Children’s Hospital Center for Vaccine Development and licensed from the built-in commercialization staff of BCM Ventures, Baylor College of Medicine.
The Center has already made an advance fee of Rs 1,500 crore to order 30 crore doses of Corbevax. Sources mentioned that Corbevax is predicted to get emergency use authorization within the subsequent two weeks.
Another candidate for a doable third dose might be Serum Institute of India’s Kovovax. It is a recombinant nanoparticle protein primarily based COVID-19 vaccine. US-based Novavax and SII have already obtained the EUA for this vaccine within the Philippines.
The third candidate for a doable third dose might be Bharat Biotech’s intranasal vaccine. Sources mentioned that this vaccine is predicted to come back within the second fortnight of January.
The fourth candidate for a doable third dose might be India’s first m-RNA COVID-19 vaccine developed by Pune-based Genova Biopharmaceuticals Ltd.
Earlier, the federal government had mentioned that Genova’s mRNA vaccines are anticipated to supply 60 million doses. More considerably, in contrast to Pfizer and Moderna’s mRNA vaccine, it may be saved on the chilly storage necessities (2-8 °C) of India’s vaccination drives.
Experts around the globe are recommending mRNA vaccines as a booster dose. In September, after reviewing knowledge on booster responses from varied combos of COVID-19 vaccines, the UK skilled physique was the primary to suggest choice for Pfizer’s mRNA vaccine to be supplied as a 3rd booster dose, Regardless of which product was used. major schedule.
,
With inputs from TheIndianEXPRESS
